Predicting the risk of new and recurrent CMV disease

 
Sep 9, 2015 1:00 PM–2:00 PM (AEST/AEDT)
Duration: 1hrs
During this short, live webinar, Professor Rajiv Khanna will discuss the importance of CMV monitoring. The discussion will cover infectious complications, which remain a leading cause of morbidity and mortality after organ transplantation. Attendees will learn about immune monitoring, which has emerged as a powerful tool to identify high-risk patients who are likely to develop serious infectious complications. They will also hear how immune monitoring technologies are being combined with adoptive immunotherapy to improve the clinical outcomes of transplant patients.

Professor Rajiv Khanna, Ph.D., FAHMS, Coordinator, QIMR-CIVD, Senior Principal Research Fellow (NH&MRC), QIMR Berhofer Medical Research Institute

After obtaining his doctorate degree from India, Professor Khanna continued his postdoctoral training at the University of Adelaide, Adelaide and Queensland Institute of Medical Research (QIMR), Brisbane Australia. In addition to his appointment as Group Leader of Tumour Immunology Laboratory, he is also a Senior Principal Research Fellow at the National Health and Medical Research Council of Australia (NH&MRC). Prof. Khanna is the founding Director of the Australian Centre for Vaccine Development. Dr. Khanna has published book chapters and over 200 scientific papers, including invited reviews, in leading journals. In the past decade, he has focused on researching the development of novel immune-based therapeutic strategies for the treatment of cancer patients and transplant recipients with viral complications. After completing multiple adoptive immunotherapy clinical trials, Prof. Khanna currently leads three clinical trials on the efficacy of T cell-based therapies for virus-associated cancers, such as nasopharyngeal carcinoma and glioblastoma. In collaboration with Australian and International biotech industry, he has helped develop novel therapeutic and diagnostic tools. One of the best examples is his collaboration with Cellestis Inc. on the QuantiFERON-CMV kit for predicting infectious complications in transplant patients (CE-IVD marked in Europe). His international biopharmaceutical organization collaboration projects include developing a prophylactic vaccine against human cytomegalovirus, which is associated with glioblastoma and birth defects in newborns. Prof. Khanna has successfully attracted independent funding from various national and international agencies (including NH&MRC and National Institutes of Health) as the Chief/Principal Investigator.